Literature DB >> 16813730

Paraneoplastic syndromes associated with small cell lung cancer.

Leena Gandhi1, Bruce E Johnson.   

Abstract

Small cell lung cancer (SCLC) is the most frequent cancer histology associated with paraneoplastic syndromes. These syndromes are typically caused by ectopic hormone production or immune-mediated tissue destruction caused by neural antigen expression from cancer cells. This antigen expression induces the production of antibodies that cross-react with neural tissue. This article discusses the most common ectopic hormone and neurologic paraneoplastic syndromes and emphasizes the relationships among antigens, clinical syndromes, and outcomes. Although ectopic hormone production has been associated with extensive-stage disease and a poorer outcome, the antibody-mediated paraneoplastic syndromes are prognostic factors associated with more favorable outcomes. Both have the potential for improvement with cancer treatment.

Entities:  

Mesh:

Year:  2006        PMID: 16813730     DOI: 10.6004/jnccn.2006.0052

Source DB:  PubMed          Journal:  J Natl Compr Canc Netw        ISSN: 1540-1405            Impact factor:   11.908


  32 in total

Review 1.  Small cell lung cancer: past, present, and future.

Authors:  Estelamari Rodriguez; Rogerio C Lilenbaum
Journal:  Curr Oncol Rep       Date:  2010-09       Impact factor: 5.075

Review 2.  Treatment of limited disease small cell lung cancer: the multidisciplinary team.

Authors:  Markus Glatzer; Achim Rittmeyer; Joachim Müller; Isabelle Opitz; Alexandros Papachristofilou; Ioannis Psallidas; Martin Früh; Diana Born; Paul Martin Putora
Journal:  Eur Respir J       Date:  2017-08-24       Impact factor: 16.671

Review 3.  Cardiothoracic manifestations of neuroendocrine tumours.

Authors:  Ramin Mandegaran; Sarojini David; Nicholas Screaton
Journal:  Br J Radiol       Date:  2016-01-19       Impact factor: 3.039

4.  Paraneoplastic syndromes (PNS) associated with Merkel cell carcinoma (MCC): A case series of 8 patients highlighting different clinical manifestations.

Authors:  Jayasri G Iyer; Kaushik Parvathaneni; Shailender Bhatia; Erica S Tarabadkar; Astrid Blom; Ryan Doumani; Jill McKenzie; Maryam M Asgari; Paul Nghiem
Journal:  J Am Acad Dermatol       Date:  2016-05-11       Impact factor: 11.527

5.  Hyponatremia is a predictor of hospital length and cost of stay and outcome in cancer patients.

Authors:  R Berardi; M Caramanti; M Castagnani; S Guglielmi; F Marcucci; A Savini; F Morgese; S Rinaldi; C Ferrini; M Tiberi; M Torniai; F Rovinelli; I Fiordoliva; A Onofri; S Cascinu
Journal:  Support Care Cancer       Date:  2015-03-05       Impact factor: 3.603

6.  Apelin beyond kidney failure and hyponatremia: a useful biomarker for cancer disease progression evaluation.

Authors:  Antonio Lacquaniti; Giuseppe Altavilla; Antonio Picone; Valentina Donato; Valeria Chirico; Patrizia Mondello; Carmela Aloisi; Grazia Marabello; Saverio Loddo; Antoine Buemi; Giuseppina Lorenzano; Michele Buemi
Journal:  Clin Exp Med       Date:  2014-01-28       Impact factor: 3.984

7.  Hyponatremia as a prognostic and predictive factor in metastatic renal cell carcinoma.

Authors:  A N Jeppesen; H K Jensen; F Donskov; N Marcussen; H von der Maase
Journal:  Br J Cancer       Date:  2010-02-09       Impact factor: 7.640

Review 8.  Oncoprotein metastasis and its suppression revisited.

Authors:  Razvan T Radulescu
Journal:  J Exp Clin Cancer Res       Date:  2010-04-09

9.  The predictive potential of hyponatremia for glioblastoma patient survival.

Authors:  Oliver D Mrowczynski; Alexandre J Bourcier; Jason Liao; Sara T Langan; Charles S Specht; Elias B Rizk
Journal:  J Neurooncol       Date:  2018-01-25       Impact factor: 4.130

10.  Receptor-Independent Ectopic Activity of Prolactin Predicts Aggressive Lung Tumors and Indicates HDACi-Based Therapeutic Strategies.

Authors:  Aurore Le Bescont; Anne-Laure Vitte; Alexandra Debernardi; Sandrine Curtet; Thierry Buchou; Jessica Vayr; Aurélien de Reyniès; Akihiro Ito; Philippe Guardiola; Christian Brambilla; Minoru Yoshida; Elisabeth Brambilla; Sophie Rousseaux; Saadi Khochbin
Journal:  Antioxid Redox Signal       Date:  2014-03-06       Impact factor: 8.401

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.